- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00394082
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab.
The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Melbourne, Florida, Stati Uniti, 32901
-
Ocoee, Florida, Stati Uniti, 34761
-
-
Illinois
-
Niles, Illinois, Stati Uniti, 60714
-
-
Indiana
-
Terre Haute, Indiana, Stati Uniti, 47802
-
-
Maryland
-
Columbia, Maryland, Stati Uniti, 21044
-
Westminister, Maryland, Stati Uniti, 21157
-
-
Missouri
-
Saint Joseph, Missouri, Stati Uniti, 64507
-
-
New York
-
Rochester, New York, Stati Uniti, 14623
-
-
Texas
-
Bedford, Texas, Stati Uniti, 76022
-
Dallas, Texas, Stati Uniti, 75246
-
El Paso, Texas, Stati Uniti, 79915
-
Odessa, Texas, Stati Uniti, 79761
-
San Antonio, Texas, Stati Uniti, 78229
-
Tyler, Texas, Stati Uniti, 75702
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
-
Norfolk, Virginia, Stati Uniti, 23502
-
Salem, Virginia, Stati Uniti, 24153
-
-
Washington
-
Burien, Washington, Stati Uniti, 98166
-
Edmonds, Washington, Stati Uniti, 98026
-
Vancouver, Washington, Stati Uniti, 98684
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Pathologically confirmed adenocarcinoma of the breast.
- Stage IV disease.
- Measurable disease (defined as the presence of at least one lesion that can be accurately measured in at least one dimension with longest diameter greater or = 1.0 cm with spiral computed tomography (CT) scan).
- Patients must not be a candidate for Herceptin therapy (i.e., patients with HER-2 positive disease (gene amplification by fluorescence in situ hybridization (FISH) or 3 + overexpression by ICH) and patients with unknown HER-2 status are ineligible unless the treating physicians has determined that Herceptin-based therapy would be inappropriate or not indicated).
- For subjects with prior anthracycline exposure, normal cardiac function including a baseline left ventricle ejection fraction >50% or above institution's lower limit of normal and a normal electrocardiogram (ECG) (as assessed by the investigator).
- At least 2 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal.
- International Normalized Ratio (INR) < 1.5 and activated partial thromboplastin time within normal limits (APTT WNL).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Female > 18 years of age.
- Patients have the following blood counts at Baseline: absolute neutrophil count (ANC) greater or equal to 1.5 x 10^9 cells/L; platelets greater or equal 100 x 10^9 cells/L; hemoglobin (Hgb) greater or equal to 9g/dL.
- Patients have the following blood chemistry levels at Baseline: aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT) less than or equal 2.5x upper limit of normal (ULN) range (less than or equal 5x ULN if patient has known liver metastases); total bilirubin greater than or equal to ULN; creatinine greater or equal to 1.5mg/dL.
- if female of childbearing potential, pregnancy test is negative within 72 hours of first dose of study drug.
- if fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
- Informed consent has been obtained.
Exclusion Criteria:
- No prior chemotherapy for metastatic or locally recurrent disease is allowed.
Prio neo-adjuvant chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies.
- if a taxane was part of the adjuvant regimen, at least 12 months must have elapsed between the last dose of the taxane and the date of diagnosis of metastatic disease.
- if a non-taxane-based adjuvant therapy was administered, at least six months must have elapsed between the last dose of the non- taxane-containing chemotherapy and the date of diagnosis of metastatic disease.
- Concurrent immunotherapy or hormonal therapy.
- Parenchymal brain metastases, including leptomeningeal involvement.
- Uncontrolled hypertension (defined as blood pressure of > 150/100 mmHg)
- NYHA Grade 2 or greater congestive heart failure
- History of coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic ASA greater than or equal to 325 mg per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH)for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.
- Urine protein:creatinine ratio less than or equal to 1.0 at screening.
- No history of cerebrovascular accident within six months of study entry.
- Active symptomatic peripheral vascular disease (e.g. aortic aneurysm, claudication) within six months of study entry.
- Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within six months of study entry.
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal process within six months of study entry.
- No serious non-healing wound, ulcer, or bone fracture
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first dose, or anticipation of need for major surgical procedure during the course of the study. No minor surgical procedure within seven days of study entry. Serious intercurrent medical or psychiatric illness, including serious active infection.
- History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer.
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
- Pregnant or nursing women.
- Patients with current sensory neuropathy of > Grade 1 will be excluded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: ABI-007 plus Bevacizumab
ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle.
Treatment continues until disease progression or intolerable toxicity.
If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
|
125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
Altri nomi:
Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given.
The first dose is one Day 1, cycle 1.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
Lasso di tempo: up to 25 months
|
Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.
|
up to 25 months
|
Kaplan-Meier Estimates for Progression-free Survival
Lasso di tempo: up to 39 months
|
Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first. Patients who do not have disease progression or have not died at the end of follow-up were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Response Evaluation Criteria in Solid Tumors (RECIST) defines progressive disease (PD) as a >= 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. |
up to 39 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: up to 39 months
|
Objective response is complete response (CR) + partial response (PR).
RECIST defines overall response of CR as the disappearance of all target and non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation.
Overall response of PR is defined as >= 30% decrease from baseline in the sum of the longest diameters of target lesions and no progression of non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation.
PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing and no appearance of new lesions.
The objective response is determined by combining the response of target and non-target lesions and the appearance of new lesion(s) or not together.
|
up to 39 months
|
Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: up to 39 months
|
Disease control is stable disease (SD) for >=16 weeks + complete response (CR) + partial response (PR).
RECIST defines SD as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease and no new lesions.
Definitions for CR and PR can be found in outcome #3.
|
up to 39 months
|
Kaplan-Meier Estimate for Duration of Response
Lasso di tempo: up to 39 months
|
Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease is defined in outcome #2. Complete response (CR) and partial response (PR) are defined in outcome #3. |
up to 39 months
|
Kaplan-Meier Estimates for Participant Survival
Lasso di tempo: up to 39 months
|
Participant survival is the time from the first dose of study drug to patient death from any cause.
Patients that did not die were censored at the last known time the patient was alive.
|
up to 39 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Danso M, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Presented at 2008 ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL. Abstract No. 1075.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie della pelle
- Neoplasie
- Neoplasie per sede
- Malattie del seno
- Neoplasie mammarie
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Agenti antineoplastici, fitogenici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Paclitaxel
- Bevacizumab
- Paclitaxel legato all'albumina
Altri numeri di identificazione dello studio
- CA043
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno metastatico
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su ABI-007
-
CelgeneRitiratoTumore solidoStati Uniti
-
CelgeneCompletatoMelanoma | MetastasiStati Uniti
-
Celgene CorporationCompletatoNeoplasie mammarie | Metastasi, NeoplasieStati Uniti
-
Celgene CorporationCompletatoNeoplasie | Metastasi, NeoplasieStati Uniti
-
Taiho Pharmaceutical Co., Ltd.Completato
-
Celgene CorporationCompletatoNeoplasie mammarie | Metastasi, NeoplasieStati Uniti
-
CelgeneCompletatoTumore del pancreasStati Uniti, Canada, Spagna, Australia, Francia, Germania, Austria, Italia, Ucraina
-
University Health Network, TorontoCelgene CorporationCompletato
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletatoCarcinoma ovarico ricorrente | Carcinoma delle tube di Falloppio | Carcinoma peritoneale primitivoStati Uniti
-
Celgene CorporationCompletatoCarcinoma polmonare non a piccole celluleStati Uniti